Inventor · disambiguated record
Qijun Qian
Also filed as: QIAN QIJUN
4 granted patents·11 pending applications·3 citations·filing 2001–2022
60Inventor score
Files withSHANGHAI CELL THERAPY RES INST4ZHEJIANG NANOMAB TECH CENTER CO LTD4QIAN QIJUN2SHANGHAI CELL THERAPY GROUP CO LTD2MAXIRNA ZHEJIANG TECH CO LTD1
Top patents by PatentIndex Score
15 records- 0164US12042515B2Killer cell capable of efficiently and stably expressing antibody, and uses thereofSHANGHAI CELL THERAPY RES INST·Filed 2017·Granted Jul 23, 2024·1 cites·14 claims
- 0261US2025345277A1Ionizable Liposome, Preparation Thereof, and Application Thereof in Gene DeliveryMAXIRNA ZHEJIANG TECH CO LTD·Filed 2022·Application pending·0 cites
- 0355US7491525B2Specific proliferation in tumour cell which can express antioncogene with high efficiency and the use of itQIAN QIJUN·Filed 2002·Granted Feb 17, 2009·2 cites·16 claims
- 0451US9029133B2Recombinant virus comprising an intact tumor-therapeutic antibody with human constant regions and the use thereofQIAN QIJUN·Filed 2004·Granted May 12, 2015·0 cites·8 claims
- 0546US2024174760A1Nanobody targeting bcma and application thereofZHEJIANG NANOMAB TECH CENTER CO LTD·Filed 2022·Application pending·0 cites
- 0646US2025333508A1CTLA-4 Binding Molecule and Use ThereofZHEJIANG NANOMAB TECH CENTER CO LTD·Filed 2022·Application pending·0 cites
- 0745US2025215092A1Human Epidermal Growth Factor Receptor Binding Molecule and Use ThereofZHEJIANG NANOMAB TECH CENTER CO LTD·Filed 2022·Application pending·0 cites
- 0844US2022372481A1Promoter having high activity in activated t-cellSHANGHAI CELL THERAPY GROUP CO LTD·Filed 2020·Application pending·0 cites
- 0944US2023058519A1Cell Expressing Immune Modulatory Molecules and System for Expressing Immune Modulatory MoleculesSHANGHAI CELL THERAPY GROUP COMPANY CO LTD·Filed 2020·Application pending·0 cites
- 1044US2024190986A1Mesothelin binding molecule and application thereofZHEJIANG NANOMAB TECH CENTER CO LTD·Filed 2021·Application pending·0 cites
- 1141US2021046113A1Dual-activating costimulatory molecule receptor and use thereofSHANGHAI CELL THERAPY RES INST·Filed 2018·Application pending·0 cites
- 1238US12358994B2Antibody-modified chimeric antigen receptor modified T cell and uses thereofSHANGHAI CELL THERAPY GROUP CO LTD·Filed 2018·Granted Jul 15, 2025·0 cites·13 claims
- 1338US2021024927A1Chimeric promoter with high transcriptional activity in t-cellsSHANGHAI CELL THERAPY RES INST·Filed 2018·Application pending·0 cites
- 1430US2018265890A1Efficient and safe transposon integration system and use thereofSHANGHAI CELL THERAPY RES INST·Filed 2016·Application pending·0 cites
- 1528US2004091996A1Virus which can express tumor angiostatin factor with high efficiency in specific tumor cells and the use of itFiled 2001·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →